Aradigm Doses First Patient In Its Second Phase 2b Clinical Trial Of Inhaled Liposomal Ciprofloxacin In Bronchiectasis Patients
Originally posted in Cystic Fibrosis News From Medical News Today
Aradigm Corporation (OTCBB:ARDM) (the “Company”) announced that it dosed the first patient in the U.S…
No Comments
RSS feed for comments on this post.
by Raelene
